Join the club for FREE to access the whole archive and other member benefits.

Insilico and ARK enter a research collaboration on health-span and longevity

AI-based methods, to explore mechanisms of ageing and improving health-span

22-May-2019

Key points from article :

Ageing Research at King's partners with Insilico to work on healthy ageing and longevity.

ARK pioneers in research on ageing while Insilico is an AI company dedicated to human productive longevity.

Aim to employ AI-based methods, to explore mechanisms of ageing and improving health-span.

An opportunity to deliver academic excellence in AI methods for ageing and longevity research.

Has significant potential to impact healthy ageing, age-related diseases and targeted therapeutics.

Mentioned in this article:

Click on resource name for more details.

Alex Zhavoronkov

CEO of InSilico Medicine & Deep Longevity. CSO of Biogerontology Research Foundation

Insilico Medicine

Biotechnology company that uses artificial intelligence to develop new drugs and for aging research

King’s College London

Public research university

Richard Siow

Director of Ageing Research at King's College London (ARK)

Topics mentioned on this page:
Ageing Research